Welcome to our dedicated page for MDB Capital Holdings LLC-A news (Ticker: MDBH), a resource for investors and traders seeking the latest updates and insights on MDB Capital Holdings LLC-A stock.
MDB Capital Holdings, LLC (NASDAQ: MDBH) is an investment holding company and public venture platform in the investment banking and securities dealing industry. News and press releases about MDB Capital highlight its focus on launching early-stage and disruptive "Big Idea" companies through public venture capital, as well as developments across its subsidiaries such as MDB Capital and PatentVest.
Readers following MDBH news can expect updates on private placements, initial public offerings, and post-IPO offerings for emerging companies that align with MDB’s investment criteria. Recent announcements describe offerings and planned offerings for companies in areas such as biopharmaceuticals and consumer products, along with the expansion of MDB’s pipeline of early-stage, disruptive companies and partnerships with investor groups and registered investment advisers.
News related to PatentVest, a division of MDB Capital Holdings, features IP-focused research and strategy. PatentVest issues PatentVest Pulse reports that analyze intellectual property and competitive landscapes in sectors including quantum computing, the space economy, and cardiac diagnostics. These reports use patent data to examine leadership, defensible IP positions, and commercialization progress across innovation-driven markets.
Additional MDBH news items cover conference presentations, investor webinars, and corporate updates, including plans to spin out PatentVest as an independent public company. For investors and observers, the MDBH news feed provides insight into the company’s ongoing financings, its role in public venture capital, and its IP-centered analysis of emerging technology markets.
Invizyne Technologies announced its corporate rebranding to eXoZymes Inc, with its stock trading symbol changing from IZTC to EXOZ on the Nasdaq Capital Market. The company introduces 'exozymes' as a new scientific concept, positioning it as the successor to synthetic biology (SynBio), particularly focusing on industrial-scale production.
eXoZymes specializes in AI-engineered enzymes designed to operate outside living cells in bioreactors, transforming feedstocks into valuable chemicals, medicines, and biofuels. The company emphasizes this technology's potential to replace traditional chemical production methods with sustainable alternatives. The development process, powered by AI and enzymes, significantly reduces production timelines, with the company expecting to announce a new chemical development completed in just weeks.
Invizyne Technologies, a designer of cell-free, enzyme-based biomanufacturing systems, announced its corporate name change to eXoZymes, Inc. The company, currently trading under NASDAQ ticker IZTC, will change its ticker symbol to EXOZ, expected to take effect on February 12, 2025, pending final approvals.
The company will update its branding, including the corporate website, to reflect the new name. Existing shareholders are not required to take any action regarding the name and ticker symbol change. The CUSIP number for the company's common stock will remain unchanged.
PatentVest has released a comprehensive report on the Continuous Glucose Monitoring (CGM) market, highlighting significant growth prospects and technological innovations in diabetes care. The report reveals that the global CGM market, valued at $11.63 billion in 2024, is projected to reach $21 billion by 2029.
The analysis addresses the critical need for continuous glucose monitoring solutions, noting that diabetes affects 537 million adults worldwide, with projections reaching 783 million by 2045. Key market drivers include technological advancements in non-invasive monitoring, integration with mobile applications, and the emergence of over-the-counter (OTC) CGM products.
The report emphasizes the competitive landscape dominated by major players like Dexcom, Abbott, Medtronic, and Roche, highlighting their role in transforming diabetes management through innovation and strategic market positioning. A surge in patent filings and ongoing litigation trends underscore the market's competitive nature.
MDB Capital Holdings (NASDAQ: MDBH) provided its Q3 2024 operational update, highlighting significant achievements including the successful IPO of Invizyne Technologies where MDB retains 48% ownership. The company launched a collaboration with Mayo Clinic for an anti-senescence platform with 67% founding ownership. MDB enhanced its analysis capabilities, screening 8,751 companies and examining 217 potential market leaders. The company expanded its investor base by 15%, increased brokerage accounts by 450+, and grew assets under management from $2M to $28M. PatentVest client engagements increased from three to eight since 2023.
Invizyne Technologies (NASDAQ: IZTC) has been awarded a $2 million project from the U.S. Department of Defense's BioMADE initiative to advance sustainable aviation fuel (SAF) capabilities. The project, in partnership with the University of Georgia, focuses on enabling enzyme production for cell-free biomanufacturing of isobutanol, a key SAF precursor. This follows previous grants totaling $5.85 million from the Department of Energy. The project aims to develop an enzyme production pipeline and deploy technology in 100L pilot-scale facilities. The global SAF market is projected to grow at 52.2% annually, reaching $27.4 billion by 2032.
MDB Capital Holdings (NASDAQ: MDBH) has scheduled a Zoom webinar for Thursday, November 21, 2024, at 4:30 p.m. Eastern Time to discuss its third quarter 2024 results. CEO Christopher Marlett will lead the presentation, accompanied by management team members, to review recent developments, ongoing initiatives, and anticipated milestones. The company will release detailed financial results before the call. Investors can pre-register for the webinar through a provided link or access it via MDB's investor relations website.
Invizyne Technologies, a designer of cell-free, enzyme-based biomanufacturing systems, announced the closing of its Initial Public Offering of 1,875,000 common stock shares at $8.00 per share. Trading began on NASDAQ under symbol IZTC on November 13, 2024. The IPO raised approximately $15 million in gross proceeds. The company granted a 45-day option to the underwriter to purchase up to 281,250 additional shares. Additionally, in a concurrent private placement, Invizyne issued 93,750 warrants at $0.125 each, exercisable at $8.00 per share for five years.
Invizyne Technologies (NASDAQ:IZTC), a designer of cell-free, enzyme-based biomanufacturing systems, began trading on Nasdaq on Nov. 13, 2024. The company, founded in 2019, is based on technology developed by UCLA Professor Emeritus James Bowie that enables enzymatic pathways to function outside living cells. CEO Michael Heltzen emphasized the company's ability to overcome traditional cell-based synthetic biology limitations through their next-generation enzymes and biomanufacturing platform, aiming to demonstrate commercial viability through licensing deals and partnerships.
Invizyne Technologies, a designer of cell-free, enzyme-based biomanufacturing systems, announced that its common shares will begin trading on the NASDAQ on November 13, 2024, at approximately 12:00pm EST under the ticker symbol 'IZTC'. The company specializes in producing commercially important molecules and chemicals for everyday life through their innovative biotechnology solutions.
Invizyne Technologies, a designer of cell-free, enzyme-based biomanufacturing systems, announced that its common shares will begin trading on the Nasdaq Capital Market on November 13, 2024, under the ticker symbol 'IZTC'. The company, which focuses on producing commercially important molecules and chemicals for everyday life, expects the offering to close on November 14, 2024, subject to customary closing conditions.